Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modelling drug-protein interactions, and predicting reaction rates.
Editor's picks
The Exascale Computing Projects, Doug Kothe, discusses the lasting impact of exascale development
DiRAC has created a structured training programme with a user feedback loop to drive training and skills development across its entire user-base
News
News
Analysis & opinion
Analysis & opinion
Features
Features
Resources
Some 50-80% of research scientists' and data scientists' time is spent wrestling with data before they can focus on higher value AI/ML and advanced analysis to help bring new life-saving therapeutics to market.
From new instruments and software to the rise of the digital lab, the landscape of analytical chemistry data continues to evolve, writes Sanji Bhal, Director, Marketing & Communications
Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modelling drug-protein interactions, and predicting reaction rates.
Press releases
Tech Focus
Laboratory informatics tools have continued to converge around requirements for data management and movement within an organisation.
A round-up of the latest technologies available to scientists and researchers using HPC
A round-up of the latest processing and memory technologies
Latest issue
Laboratory informatics tools have continued to converge around requirements for data management and movement within an organisation.
A round-up of the latest technologies available to scientists and researchers using HPC
A round-up of the latest processing and memory technologies